LocoMMotion

janssen
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

LocoMMotion Study Patient Selection Checklist

- ☐ Documented diagnosis of multiple myeloma according to IMWG diagnostic criteria
- ☐ Previous treatment with a PI,* an IMiD† and an anti-CD38 monoclonal antibody‡
- ☐ Number of prior lines:
  - ☐ Received ≥3 prior lines of therapy
  - **OR**
  - ☐ Received ≤2 prior lines of therapy and double refractory to a PI and an IMiD
- ☐ ECOG performance status grade of 0 or 1
- ☐ New line of treatment will start within the next 28 days
- ☐ Evidence of progressive disease:
  - ☐ Documented evidence of progressive disease on or after the last regimen
  - **OR**
  - ☐ Best response to the last regimen was "stable disease" and documented evidence of progressive disease within the last 6 months
- ☐ Measurable disease as defined by any of the following:
  - ☐ Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL
  - **OR**
  - ☐ Urine monoclonal paraprotein (M-protein) level ≥200 mg/24 hours
  - **OR**
  - ☐ Light chain multiple myeloma without measurable disease in the serum or the urine (serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)
- ☐ ≥18 years
- ☐ Not pregnant and does not plan to become pregnant within the study period

ECOG = Eastern Cooperative Oncology Group; IMiD = Immunomodulatory agent; IMWG = International Myeloma Working Group; PI = Proteasome inhibitor
*PIs include bortezomib, ixazomib, carfilzomib, MLN9708, marizomib, oprozomib etc.
†IMiDs include thalidomide, lenalidomide, pomalidomide etc.
‡Anti-CD38 monoclonal antibodies include daratumumab, isatuximab, TAK-079, MOR202 etc.

Study ID: 68284528MMY4001 ClinicalTrials.gov Identifier: NCT04035226

LocoMMotion Study Patient Selection

Decision Tree



ECOG = Eastern Cooperative Oncology Group; IMiD = Immunomodulatory agent; IMWG = International Myeloma Working Group; PI = Proteasome inhibitor

*PIs include bortezomib, ixazomib, carfilzomib, MLN9708, marizomib, oprozomib etc.

†IMiDs include thalidomide, lenalidomide, pomalidomide etc.

‡Anti-CD38 monoclonal antibodies include daratumumab, isatuximab, TAK-079, MOR202 etc.

Study ID: 68284528MMY4001 ClinicalTrials.gov Identifier: NCT04035226